Twice-Yearly HIV shot could replace daily pill regimen

NCT ID NCT07683000

Not yet recruiting Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a combination of two broadly neutralizing antibodies (teropavimab and zinlirvimab) plus a capsid inhibitor (lenacapavir), given as injections just twice a year, can keep HIV under control as well as daily oral medications. The study enrolls adults with HIV-1 whose virus is already suppressed. Participants either switch to the long-acting injectable regimen or continue their usual daily pills. The main goal is to see if the injectable regimen maintains viral suppression at 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenacapavir, teropavimab, and zinlirvimab
What this could lead to: If successful, this could offer people with HIV a twice-yearly injection instead of daily pills, simplifying treatment and improving adherence.
What could go wrong: This is an early-phase 3 trial, so results may not confirm long-term safety or efficacy. Some participants may experience side effects or viral rebound.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV -1 INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.